C4 Therapeutics, Inc., based in Watertown, Massachusetts, is an innovative biopharmaceutical company focused on developing therapeutic candidates that leverage its proprietary dynamic protein degradation platform to target and eliminate harmful proteins associated with oncology and neurodegenerative diseases. The company's advanced approach aims to address significant unmet medical needs, positioning C4 Therapeutics as a leader in redefining treatment paradigms in the biopharmaceutical sector. With a strong commitment to improving patient care and clinical outcomes, C4 is poised to make a substantial impact in the life sciences industry. Show more

Location: 490 ARSENAL WAY, WATERTOWN, MA, UNITED STATES, 02472, Watertown, MA, 02472, USA | Website: https://www.c4therapeutics.com | Industry: BIOTECHNOLOGY | Sector: HEALTHCARE

Market Cap

184.1M

52 Wk Range

$1.08 - $3.72

Previous Close

$1.96

Open

$1.95

Volume

1,670,000

Day Range

$1.83 - $1.96

Enterprise Value

59.53M

Cash

58.81M

Avg Qtr Burn

-31.21M

Insider Ownership

7.20%

Institutional Own.

73.79%

Qtr Updated

09/30/25

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Cemsidomide (CFT7455) +/- dexamethasone Details Hematologic malignancies, Blood disorder, Non-Hodgkin lymphoma, Blood cancer, Multiple myeloma	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CFT1946 (mono) +/- cetuximab Details Cancer, V600 Mutant Cancers, Solid tumor/s, Colorectal cancer, Melanoma	Phase 1/2 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CFT8919 (EGFR) Details Solid tumor/s, Non-small cell lung carcinoma, Cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
CFT8634 (BiDAC) Details Rare diseases, Cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.